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CASE PRESENTATION
Patient 1. A 17-year-old boy with gross hematuria was
referred to our center 18 years ago. He had been hit on
the left flank area during a football scrimmage. His father
and uncle had autosomal-dominant polycystic kidney dis-
ease (ADPKD). On examination, his height was 1.88 m;
weight, 73.2 kg; and blood pressure (BP), 160/100 mm Hg.
Moderate left costovertebral angle tenderness was noted.
The serum creatinine was 0.9 mg/dL. Ultrasound exami-
nation disclosed kidneys of 12.8 and 12 cm with multiple
cysts. No cysts appeared in the liver or pancreas. After
resting for 30 minutes, the BP was 130/80 mm Hg. He re-
turned for follow-up 1 year later. The BP was 145/92 mm
Hg; enalapril, 5 mg daily, was started.
Between 1988 and 1999, he was followed by his family
physician and made occasional visits to our center. Four-
teen years ago, he returned for a study on the accuracy
and reproducibility of kidney volume measurements by
electron beam computed tomography (CT). His weight
was 81.6 kg and BP 138/86 mm Hg. The serum creati-
nine was 1.0 mg/dL. The total kidney volume was esti-
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mated to be 1120 mL (Fig. 1A). The dose of enalapril
was increased to 10 mg daily. During the next 6 years,
he remained active, working as a plumber, and was fol-
lowed at home. Eight years ago, he returned with in-
creasing systolic BPs, between 145 and 160 mm Hg. His
weight was 98 kg and BP 160/90 mm Hg. Palpable poly-
cystic kidneys and a small umbilical hernia were noted.
The serum creatinine and iothalamate clearances were
1.3 mg/dL and 111 mL/min/1.73 m2. Proteinuria (urine
protein/osmolality ratio of 0.28) was detected for the
first time. The administration of enalapril was changed to
lisinopril, 20 mg daily. Six years ago, total kidney volume
was 1568 mL (Fig. 1B and C). Treatment with atorvastatin
was initiated for hypercholesterolemia.
Over the next 5 years, he was followed yearly in our
center. Moderate polyuria was noted on 24-hour urine
collections, averaging 3162 mL. By his account, he had
always drunk lots of water. The administration of lisino-
pril was increased to 20 mg twice daily; candesartan was
added later and increased to 16 mg daily with the goal
of maintaining a systolic BP below 130 mm Hg. At the
most recent visit, last year, his weight was 107 kg; BP,
120/80 mm Hg; serum creatinine, 1.1 mg/dL; iothala-
mate clearance, 81 mL/min/m2; urine albumin excretion,
119 mg/24 hours; and total kidney volume measured by
magnetic resonance, 2217 mL (Fig. 1D). Figure 2 summa-
rizes the kidney volume, serum creatinine, iothalamate
clearance, and first morning urine osmolality values over
17 years of follow-up.
Patient 2. A 31-year-old man was admitted to a local
hospital in 1972 for acute-onset right flank pain and gross
hematuria. An excretory urogram showed that the right
kidney was considerably larger than the left, with a de-
layed nephrogram and a filling defect in the renal pelvis
consistent with a clot (Fig. 3A and B). A right ureteral
catheter was placed, and he was referred to our cen-
ter. Several members of his family had died from com-
plications of ADPKD. His height was 1.75 m; weight,
77 kg; and BP, 148/102 mm Hg. An enlarged, tender, right
polycystic kidney was palpable. The gross hematuria and
urinary obstruction resolved, and the serum creatinine
concentration decreased from 1.8 to 1.3 mg/dL without
further treatment. Hydrochlorothiazide-spironolactone
was prescribed for hypertension.
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Fig. 1. Renal imaging studies illustrating the
evolution of polycystic kidney disease in pa-
tient 1. Axial computed tomography images
from 1991 and 1999 (A and B) and coronal T2-
weighted images from 1999 and 2004 (C and
D) showing the increase in total kidney and
cyst volumes and the reduction in parenchy-
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Fig. 2. Changes in total kidney volume, iothalamate clearance, serum creatinine concentration, and urine osmolality values over time in patients
1 and 2. The first total kidney volume in patient 1 (age 17 years) was derived from the renal ultrasound using the ellipsoid formula. The remaining
total kidney volumes were measured using computed tomography or magnetic resonance images.
Between 1974 and 2003, he was followed regularly in
our clinic. It was noted in the history that he had liked
to drink abundant fluids since childhood. The average
24-hour urine output prior to a decline in renal function
was 2330 mL. Multiple urinalyses showed trace to 1+
proteinuria. The hypertension was consistently well con-
trolled, initially with hydrochlorothiazide-spironolactone
and later with the addition of atenolol. These were later
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Fig. 3. Renal imaging studies illustrating the
evolution of polycystic kidney disease in pa-
tient 1. Excretory urograms in 1972 show an
enlarged right kidney with a delayed and pro-
longed nephrogram (A and B). Axial com-
puted tomography images (C and D) showing
the increase in total kidney and cyst volume
between 1999 and 2003; note also the devel-
opment of aortic wall calcification.
replaced with enalapril, with the subsequent addition of
amlodipine and labetalol. Hyperlipidemia was controlled
initially with lovastatin and later simvastatin. In 1990 and
1999 he participated in studies on the accuracy and repro-
ducibility of renal volume measurements and longitudi-
nal analysis of renal volume changes by electron beam CT
in ADPKD (Fig. 3C). A follow-up CT scan also was ob-
tained 2 years ago (Fig. 3D). The renal volume increased
from 1975 mL in 1990 to 2704 mL in 1999 and 3728 mL
in 2003. The changes in renal volume were associated
with a progressive decline in iothalamate clearance and
an increase in serum creatinine from 1.2 mg/dL in 1974
to 5.7 mg/dL in 2003.
DISCUSSION
DR. VICENTE E. TORRES (Division of Nephrology,
Mayo Clinic College of Medicine, Rochester, Minnesota):
Cyst development and growth, impaired urinary concen-
trating capacity, hypertension, and low-grade proteinuria
are often undetected manifestations of ADPKD, occur-
ring decades before renal function starts declining. Con-
cerns about medical insurability are an impediment to
early detection and prevention of complications of this
disease in the United States. Despite awareness of the
increased risk associated with a family history of the dis-
ease, frequently the diagnosis is made only after an acute
manifestation. The two patients presented here illustrate
this point as well as the inexorable progression from early
disease by 17 years of age in Patient 1 to end-stage re-
nal failure by age 62 years in Patient 2. I would like to
suggest that the development of cysts, impaired urinary
concentration, hypertension, and low-grade proteinuria
during this silent phase of the disease are intimately re-
lated and forecast the development of renal insufficiency
many years later. I also will suggest that vasopressin and
other hormonal systems exert a modulatory effect on
the abnormal cellular phenotype and cyst development
caused by PKD mutations. Understanding these interac-
tions is key to the development of effective therapies for
ADPKD.
Renal concentrating defect and plasma vasopressin levels
Martinez-Maldonado et al [1] pointed for the first time
to the prevalence of impaired renal concentrating capac-
ity in patients with ADPKD. D’Angelo et al [2], Preuss
et al [3], and Gabow et al [4] confirmed these observa-
tions. In fact, the inability to concentrate the urine max-
imally was part of a proposed algorithm in screening
for ADPKD [2–4]. More recently, Kaariainen, Koskimies
and Norio [5] and Seeman et al [6] have shown that ap-
proximately 60% of children with ADPKD cannot con-
centrate the urine maximally after the administration of
1-desamino-[D-Arg8]-vasopressin (dDAVP). Consistent
with this concentrating defect, ADPKD patients, like the
two patients described here, often exhibit mild degrees of
polyuria and like to drink water. Impaired renal concen-
trating capacity also occurs in other human renal cystic
diseases, such as autosomal-recessive PKD (ARPKD),
nephronophthisis, and Bardet-Biedl syndrome, and in the
animal models of PKD in which it has been studied.
The cause of the renal concentrating defect in PKD
is not known. A central defect can be ruled out,



























Fig. 4. Effects of OPC-31260 on the develop-
ment of polycystic kidney disease. Adminis-
tration of OPC-31260 to male pcy mice (0.1%,
4-30 weeks), PCK rats (0.1%, 3-10 weeks), and
Pkd2WS25/− mice (0.05%, 3-16 weeks) at the
specified concentrations and ages markedly
inhibited renal enlargement (upper panel).
Representative kidney sections from control
(A and B) and treated (D and E) pcy mice
and PCK rats. Kidney sections from the most
severely affected control (C) and treated (F)
Pkd2WS25/− mice. Modified from [9, 10].
because plasma vasopressin levels are increased in human
ADPKD [6, 7] and in animal models where it has been as-
certained (Gattone VH, personal communication). Pos-
sible renal causes could be a defect in the principal cells
directly linked to the PKD cellular phenotype, early de-
velopment of tubulointerstitial disease, or disruption of
the corticomedullary architecture by the cysts. The up-
regulation of aquaporin 2 (AQP2) in polycystic kidneys
[8–10], in sharp contrast to other forms of nephrogenic
diabetes insipidus, suggests increased vasopressin activ-
ity and a defect distal to the production of AQP2. The
inverse correlation between renal concentrating capacity
and extent of cystic disease in children with early ADPKD
suggests that the concentrating defect occurs early and
is not primarily due to development of tubulointerstitial
lesions or disruption of the corticomedullary architec-
ture [6]. Increased plasma vasopressin levels in ADPKD
might represent the body’s attempt to compensate for
the reduced concentrating capacity of the polycystic kid-
neys and could contribute to the development of renal
cysts, hypertension, and renal insufficiency. I will briefly
consider the possible effects of vasopressin on the devel-
opment of hypertension early and on the progression of
renal insufficiency late in the disease before discussing in
more detail recent advances in the understanding of renal
cystogenesis and how this can be influenced by hormonal
factors.
Vasopressin and hypertension
The observation that plasma vasopressin levels are in-
creased in ADPKD [7, 11], particularly in patients with
hypertension, raises the issue of whether vasopressin (V)
contributes to the development of hypertension in this
disease. This could explain the inverse correlation be-
tween urine concentrating capacity and average 24-hour
blood pressures in children with ADPKD [6] and pos-
sibly the direct correlation between urine volume and
mean arterial blood pressure detected in the Modifica-
tion of Diet in Renal Disease (MDRD) study [12]. V1a
and V2 receptors mediate vasopressin’s effects on blood
pressure. V1a receptor activation might increase blood
pressure by a direct effect on vascular smooth muscle
and by reducing medullary renal blood flow and pressure
natriuresis [13]. V2 receptor activation increases beta
and gamma epithelial sodium channel (ENaC) expres-
sion and ENaC function and acts synergistically with al-
dosterone in the cortical collecting duct (CCD) [14]. On
the other hand, V2 receptor activation also might exert
an antihypertensive effect by inducing nitric oxide (NO)
synthesis in collecting ducts and by increasing medullary
blood flow [15]. Impaired NO synthesis, which has been
reported in human ADPKD and in animal models of
PKD [16, 17], might be a prerequisite for the hyperten-
sive effect of vasopressin. Vasopressin might play a role
in salt-sensitive forms of human and experimental hy-
pertension. Plasma vasopressin levels are higher in “low-
renin” and African American hypertensive patients than
in normotensive subjects [18]. In untreated hypertensive
individuals, plasma vasopressin levels correlate with both
systolic and diastolic BP. Vasopressin levels are increased
in deoxycorticosterone acetate (DOCA)-salt, Dahl salt-
sensitive, Sabra salt-sensitive, and spontaneously hy-
pertensive (SHR) rats. Brattleboro rats with central
diabetes insipidus do not develop hypertension when
treated with DOCA-salt unless they are supplemented
with vasopressin [19]. Dahl salt-sensitive rats have a re-
duced renal medullary NO synthase activity that makes
them more susceptible to the hypertensive effects of va-
sopressin [20]. Vasopressin regulates the expression of
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beta and gamma subunits of ENaC in collecting ducts
of Sabra rats [21]. Up-regulation of V1a receptors in pre-
glomerular vessels [22] and of V2 receptors [23] in collect-
ing ducts is thought to play a role in the development of
hypertension in the SHR. The relevance of these observa-
tions to ADPKD-associated hypertension, which exhibits
many features of salt-sensitive hypertension, deserves
consideration.
Vasopressin and progression of chronic
renal insufficiency
Plasma vasopressin levels are increased in patients
with, and animal models of, chronic renal insufficiency
[24, 25]. Administration of vasopressin or dDAVP to nor-
mal rats elevates urea concentration in the thick ascend-
ing limb of Henle by increasing intrarenal urea recycling
and reduces sodium chloride concentration at the macula
densa; these alterations suppress tubuloglomerular feed-
back and increase glomerular filtration rate (GFR) [26,
27]. Administration of dDAVP to healthy subjects or rats
increases urine albumin excretion; this effect is in part me-
diated by activation of the renin-angiotensin system [28].
Chronic administration of dDAVP to normal rats induces
renal hypertrophy, tubular dilation, and tubulointerstitial
disease [29]. These effects of vasopressin might be par-
ticularly relevant to the compensatory hypertrophy and
progressive glomerular and interstitial fibrosis that oc-
cur in chronic kidney disease. Doubling the daily water
ingestion in 5/6 nephrectomized rats lowers plasma vaso-
pressin, urine osmolality, proteinuria, BP, compensatory
renal hypertrophy, glomerulosclerosis, and tubulointer-
stitial fibrosis [25, 30]. That the attenuation of progression
of renal disease in 5/6 nephrectomized Brattleboro rats is
reversed by the administration of dDAVP suggests that
V2 receptors play a major role in the deleterious influ-
ence of vasopressin on disease progression [27]. Contrary
to these observations, a retrospective analysis of MDRD
patients with baseline GFRs of 25 to 55 mL/min/1.73 m2
raised the possibility that a high fluid intake could be
detrimental to patients with chronic renal insufficiency,
particularly to those with ADPKD [12]. The patients with
the greater urine volumes and the lowest urine osmolali-
ties experienced the fastest declines in GFR. Since these
patients tended to have lower serum sodium concentra-
tions and had urines hypotonic to plasma, the authors
concluded that excess water intake and not a renal con-
centrating defect caused the high urine volume. Further
studies will be necessary to elucidate the potential benefi-
cial or detrimental effects of high fluid intake in ADPKD
patients with renal insufficiency.
Hormonal modulation of cystogenesis
Since the initial cloning of PKD1 in 1994, the pace of
research in ADPKD has accelerated, and an understand-
ing of the PKD phenotype at a cellular level is emerg-
ing. I will briefly review these advances and discuss the
potential benefits of vasopressin antagonists and related
therapies.
Polycystins and [Ca2+]i homeostasis. Polycystin-1 and
polycystin-2, the proteins mutated in ADPKD, play an
important role in the regulation of [Ca2+]i homeosta-
sis (see [31] for a recent review). Polycystin-1 has a
large extracellular region, 11 transmembrane domains,
and a short cytoplasmic tail. The extracellular region
has homology to domains usually involved in protein-
protein or protein-carbohydrate interactions and to a
family of sperm-expressed sea urchin proteins involved
in sperm/egg interactions and the acrosome reaction. The
C-terminal tail of polycystin-1 physically interacts with,
and regulates the function of, polycystin-2 and also might
activate a number of intracellular pathways (G protein,
Wnt, and JAK/STAT signaling). Polycystin-2 is smaller
than polycystin-1 and is predicted to have cytoplasmic N-
and C-termini and 6 transmembrane domains. It acts as
a Ca2+-permeable cation channel and its transmembrane
region has homology to transient receptor potential chan-
nel (TRPC) subunits.
The polycystins are found in many subcellular loca-
tions, polycystin-1 in focal adhesions, desmosomes, ad-
herens, and tight junctions, and polycystin-2 mostly in
the endoplasmic reticulum and possibly, to a much lesser
extent, in the plasma membrane (see [31] for a recent
review). Polycystin-1 in the plasma membrane might in-
teract with polycystin-2 in the adjacent endoplasmic retic-
ulum, similar to the conformational coupling of TRPCs
in the plasma membrane and 1,4,5-triphosphate (IP3) re-
ceptors in the endoplasmic reticulum. Polycystin-2 also
physically interacts with TRPC1 [32]. Overexpression of
polycystin-2 in LLPCK cells amplifies the Ca2+ release
from intracellular stores in response to vasopressin stim-
ulation [33]. In vascular smooth muscle cells, a Pkd2
haplo-insufficient state (that is, polycystin-2 content half
of normal) is sufficient to significantly reduce capacita-
tive calcium entry and sarcoplasmic reticulum Ca2+ stores
[34]. In drosophila, a Pkd2 haplo-insufficient state can-
not mediate optimal smooth muscle contractility [35].
Increases in [Ca2+]i evoked by platelet-activating fac-
tor are reduced in B-lymphoblastoid cells isolated from
patients with PKD1 or PKD2 mutations [36]. Deple-
tion of polycystin-1 in 293 or Madin-Darby canine kid-
ney (MDCK) cells by an antisense oligodeoxynucleotide
to levels approximately one-half those found in control
cells induces cell proliferation and premature G1/S-phase
transition [37]. Insertion of a neomycin cassette into in-
tron 1 of Pkd1 reduced Pkd1 transcript levels to 20%
of control because of aberrant splicing and caused poly-
cystic kidneys [38]. This animal model demonstrates that
cystogenesis might result from a reduction in polycystin-
1 levels and does not always require complete lack or
inactivation of this protein.
Recent studies have focused on the localization of
the polycystin complex in primary cilia and on its
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well-documented role in mediating calcium fluxes in
response to mechanical stimulation [39, 40]. Every ep-
ithelial cell in the kidney, with the exception of the inter-
calated cells, is decorated by a single primary cilium. A
primary cilium consists of a membrane continuous with
the cell membrane and a central axoneme comprising
nine microtubule doublets [41–43]. The cilium originates
from, and is rooted in, a basal body or mother centriole
in the centrosome. The centrosome is found in proximity
to the Golgi apparatus and constitutes the microtubule
organizing center of the cell. It consists of a mother and a
daughter centriole and pericentriolar material surround-
ing the mother centriole. In non-dividing cells, the distal
end of the mother centriole gives rise to the primary cil-
ium. The primary cilium in differentiated renal epithelial
cells has mechanosensory and chemosensory functions
[44, 45]. During the S-phase, the primary cilium is reab-
sorbed and the centrioles duplicate into new mother and
daughter centrioles. During mitosis the new centrosomes
are at the poles of the mitotic spindle and primary cilia
are absent. Growth and reabsorption of the primary cil-
ium during the cell cycle require continuous transport
of proteins to and from the tip of the cilia. This trans-
port occurs in aggregates called rafts and is driven by
two motor proteins, kinesin II (anterograde) and cyto-
plasmic dynein (retrograde transport). Disruption of pri-
mary cilia in principal cells by a kidney-specific knockout
of a kinesin II subunit (KIF3A) results in rapid develop-
ment of polycystic kidneys [46]. Inactivation of hepato-
cyte nuclear factor-1b (HNF1b), a transcription factor in
the ciliary and basal body proteome, down-regulates the
expression of five PKD proteins (uromodulin, fibrocystin,
polycystin-2, nephrocystin-1, and polaris) and results in
polycystic kidneys [47, 48]. The association of proteins
mutated in PKDs and the centrosome is not limited to
the interphase. It also occurs during mitosis, as it has been
reported for inversin, BBS4, and polycystin-2 [49–51].
Loss of polycystin-2 localization to the mitotic spindles by
knockdown of the interacting cytoskeletal protein mDia1
blunts histamine-evoked increases of [Ca2+]i in dividing
cells [51].
Role of cyclic adenosine monophosphate (cAMP) in
cystogenesis. In the last two decades, many studies have
established that the development of PKD is characterized
by a switch from a well-differentiated, non-proliferative,
mainly reabsorptive cellular phenotype to a partially de-
differentiated, secretory phenotype characterized by po-
larization defects and high rates of proliferation and
apoptosis [52]. Researchers at the University of Kansas
Medical Center have gathered a wealth of evidence point-
ing to a major role for cAMP in cystogenesis by pro-
moting fluid secretion and cell proliferation (see [53]
for a review). Initially, they reported that cAMP stim-
ulates growth of MDCK cell subconfluent monolayers,
increases transepithelial movement of fluid across polar-
ized MDCK cell monolayers on permeable supports, and
contributes to enlargement of MDCK and ADPKD mi-
crocysts in hydrated-collagen gels. Further studies estab-
lished that fluid secretion by ADPKD epithelia, as well
as by normal collecting ducts, is driven by chloride en-
tering the cell via basolateral Na+/Cl− or Na+/K+/2 Cl−
co-transporters and exiting via apical cAMP-dependent
Cl− channels. Then they noted, along with other in-
vestigators [54], that cAMP activates the extracellular
signal-regulated protein kinase (ERK) cascade and in-
creases the proliferation of ADPKD cells while exerting
inhibitory effects on normal human kidney cortex cells.
The observation that treatment of collecting duct princi-
pal (M-1) cells with calcium channel blockers replicates
the abnormal proliferative response of the ADPKD cells
to cAMP suggested a link between the cystic phenotype
and the reduction in [Ca2+]i that likely results from dis-
rupting the polycystin pathway. More recently, the Kansas
group has shown that prolonged (at least 3 hours) incu-
bation of principal cells in a low calcium medium or in
the presence of calcium channel blockers allows cAMP
activation of a B-Raf/ERK pathway and stimulation of
cell proliferation in a protein kinase A (PKA)-, Src- and
Ras-dependent manner [55]. The effect of calcium re-
striction was thought to be due to phosphatidylinositol
3′-kinase (PI3K) and Akt inhibition, since it was repli-
cated by PI3K or Akt inhibitors. Duration of calcium re-
striction for at least 3 hours was deemed necessary to
increase B-Raf 95 kD in the cells via adjustments in syn-
thesis and/or turnover rate. Since transfection of prin-
cipal cells with a dominant negative polycystin-1 C-tail
construct induced cAMP-dependent B-Raf and ERK ac-
tivation, inhibitable by a calcium ionophore, the authors
concluded that the proliferative cellular phenotype of
polycystic kidney disease is directly linked to abnormal-
ities in [Ca2+]i homeostasis. The central role that 95 kD
B-Raf plays in the cAMP-responsive proliferative phe-
notype of the cystic epithelium also has been observed in
other cells, where it might depend on the cellular density
of the culture. For example, cAMP increases ERK phos-
phorylation and cell proliferation in subconfluent normal
human keratinocytes expressing 95 kD B-Raf, but it is
inhibitory in confluent cells that express only 62 kD B-
Raf [56]. Therefore, it is intriguing to speculate that the
proliferative phenotype of the cystic epithelium results
from the cell’s failure to reach terminal differentiation
and switch B-Raf expression from the 95 kD to the 62 kD
isoform.
Recent studies in animal models of PKD suggest that
increased renal accumulation of cAMP is a feature com-
mon to most, if not all, models of this disease [9, 10, 57].
The underlying mechanism has not been established, but
a number of hypotheses can be considered. The PC1 C-
terminal tail binds heterotrimeric G proteins and possibly
acts as an atypical G protein-coupled receptor (GPCR)
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which, when activated by ligand binding or extracellular
matrix proteins, initiates Gi-mediated signaling [58]. By
this mechanism, PC1 might regulate intracellular cAMP,
and a disruption of its function could result in the el-
evated levels. A reduction in [Ca2+]i due to disruption
of the polycystin pathway could stimulate calcium-
inhibitable AC6 [59] and inhibit calcium/calmodulin-
dependent PDE1 [60]. AC6 is the main AC isoform
and PDE1, along with PDE4, is the main phosphodi-
esterase (PDE) isoform in the collecting duct principal
cells. Some PDE4 isozymes are phosphorylated and in-
hibited by ERK2 [61], which is known to be activated
in PKD. Up-regulation of the vasopressin V2 receptor,
found in all the models in which vasopressin V2 recep-
tor expression has been studied (cpk, pcy, Pkd2−/WS25,
and HNF1b knockout mice and PCK rat) [8–10, 47],
might play a role. Finally, abnormal AQP2 trafficking due
to altered [Ca2+]i homeostasis or disrupted medullary
architecture due to cysts could be responsible for the
concentration defect common to all forms of PKD; in
this scenario, the increased cAMP levels could repre-
sent a maladaptive response in an attempt to compen-
sate for the concentration defect. Consistent with this
possibility are the increased circulating vasopressin levels
in human ADPKD [11] and the vasopressin-dependent
up-regulation of AQP2 mRNA in several animal mod-
els of PKD (cpk, pcy, Pkd2−/WS25, and HNF1b knockout
mice and PCK rat) [8–10, 47].
Origin of the cysts in ADPKD. Since cAMP modulates
cellular functions in a cell-specific manner, the cellular
composition of the cysts might be relevant to their patho-
genesis and the capacity of pharmacologic interventions
to influence the course of PKD. While there is general
agreement that the cysts in ARPKD and nephronophthi-
sis derive from collecting ducts, the cysts in ADPKD have
been thought to arise equally from all segments of the
nephron and collecting ducts. This view has been based
on microdissection studies performed in the 1960s and
1970s. The initial study by Osathanondh and Potter [62]
on a heterogeneous group of type 3 polycystic kidneys, in-
cluding organs with trisomy 13-15, tuberous sclerosis, and
horseshoe kidney, concluded that collecting duct branch-
ing is abnormal and that cysts derive from all segments of
the nephron and collecting duct. A study by Heggo¨ [63] on
six adult polycystic kidneys also concluded that collecting
duct branching is abnormal, that cysts arise most often in
Bowman’s capsule, the angle of the loop of Henle, and
(especially) the collecting tubules, and that cysts from col-
lecting tubules are definitely larger. Later studies by Baert
and Steg [64] on 50 kidneys from normal subjects younger
than 20 years or older than 50 years concluded that sim-
ple cysts derive from the distal nephron and collecting
tubules. Baert’s subsequent study of kidneys from two pa-
tients with early ADPKD concluded, without providing
a quantitative analysis, that ADPKD cysts derive from all
segments of the nephron and collecting tubules [65]. Con-
trary to previous microdissection studies, he found that
the collecting duct branching is normal and attributed
the previous findings to diffuse enlargement of collecting
tubules. A detailed histochemical study of 10 ADPKD
kidneys, in which cysts were defined as tubular dilations
at least 1 mm in diameter, challenged the microdissection-
based view of the origin of the cysts. In this study, 70%
of the cysts stained positively for collecting duct markers,
while the remaining 30% were negative for all markers,
possibly because of cellular dedifferentiation [66]. Simi-
lar results have been obtained in the Pkd2−/WS25 mouse
model of ADPKD [10, 67] and a new Pkd1nl/nl model
of ADPKD [38]. Other studies using AQP antibodies
showed that 30% of the cysts, but only 11% of large cysts,
were positive for AQP1 (presumably from proximal tubu-
lar origin) [68]. Because these observations were made
mostly in kidneys with advanced or end-stage renal dis-
ease, it is possible that obstruction and acquired renal
cystic disease could account for the observed proximal
tubular dilations and small cysts. It seems likely that in
ADPKD, as in ARPKD and nephronophthisis, cysts are
predominantly of collecting duct origin, at least at early
stages. Consistent with this interpretation is the obser-
vation that epithelial cells from human ADPKD cysts in
primary culture exhibit a much larger cAMP response
to dDAVP and vasopressin than to parathyroid hormone
[69].
Regulation of cAMP levels in principal cells of collecting
tubules. Multiple hormones acting on GPCRs regulate
cAMP levels in collecting duct principal cells [70, 71].
Binding of hormones to GPCRs activates signal trans-
duction through coupling of receptors to heterotrimeric
G proteins in the plasma membrane [72]. These are com-
posed of an a subunit with high affinity for guanine nu-
cleotides and b and c subunits forming a tightly linked
dimer. When an agonist binds to the receptor, GDP is
released from the a subunit and replaced with GTP. This
exchange results in dissociation of the a subunit from
the bc dimer, which is then free to interact with effectors.
Intrinsic GTPase hydrolyzes the bound GTP to GDP, dis-
sociating the a subunit from the effector, and allows it to
reassociate with the bc dimer. The G proteins are classi-
fied by their a subunits into subfamilies that have func-
tional receptor and effector interactions. Gs stimulates,
and Gi inhibits, adenylyl cyclase. Gq regulates phospho-
lipase C b-isoforms.
Vasopressin and catecholamines are the main hor-
monal modulators of adenylyl cyclase activity in the
collecting duct principal cells. Vasopressin binds to two
GPCRs, V2 and V1a [73]. V2 receptors on the basolateral
membrane are coupled to Gs, activate AC6, increase in-
tracellular cAMP levels, activate PKA, and induce Ca2+
release from intracellular stores mediated by RyR1. The
V1a receptors, present on both apical and basolateral
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membranes, are coupled to Gq; stimulate phospholi-
pase C, phosphoinositide hydrolysis, and Ca2+ release
from the endoplasmic reticulum; and might limit the V2-
induced effects on water permeability. The influence of
Gs-coupled b-adrenergic receptors on cAMP generation
is small in freshly dissected collecting ducts, the maxi-
mal response to isoproterenol being only 3% to 6% of
the maximal vasopressin response [74]. However, it in-
creases five- to sixfold in primary cultured collecting duct
cells. Alpha2-adrenergic receptors are coupled to Gi and
inhibit vasopressin-stimulated adenylyl cyclase activity
and the hydro-osmotic effect of vasopressin. Contrary
to the b-adrenergic effect, adenylyl cyclase inhibition
by epinephrine (in the presence of propranolol) acting
via a2-adrenergic receptors is markedly blunted in cul-
tured, as compared to freshly isolated, inner medullary
collecting ducts. These quantitatively different effects of
b-adrenergic and a2-adrenergic stimulation in freshly
dissected tubules and primary cultured cells could ac-
count for the rank order of cAMP responses to hormonal
stimulation (epinephrine > desmopressin > adenosine
> prostaglandin E2 (PGE2) > parathyroid hormone)
observed in primary cultured cells from ADPKD and
ARPKD kidneys [69].
Many other agents in addition to vasopressin and cate-
cholamines affect cAMP concentrations in the collecting
ducts. However, when studied at high concentrations or in
isolation on cultured cells, their effects might not be ap-
plicable to in vivo physiologic conditions. For example,
PGE2 at high concentrations stimulates cAMP produc-
tion via Gs-coupled EP4 receptors and elicits a modest
increase in water permeability. At more physiologic con-
centrations and in the presence of vasopressin, however,
it causes a Gi-coupled EP3-receptor-mediated inhibition
of adenylyl cyclase and possibly an EP1-mediated ele-
vation of [Ca2+]i and stimulation of phosphodiesterases,
both of which reduce cAMP levels and water reabsorp-
tion [75–77]. The inhibitory effects on freshly isolated
cells disappear when cells are cultured [78]. Similarly,
adenosine can stimulate cAMP production via a Gs-
coupled A2 receptor at high concentrations, but cause
a Gi-coupled A1-mediated inhibition of cAMP gener-
ation and water permeability at lower concentrations
[79–81]. Endothelin causes an ETB receptor-mediated
inhibition of vasopressin-stimulated cAMP accumulation
in freshly prepared collecting ducts and induces water
diuresis in vivo [82]. At very high concentrations, so-
matostatin can have a vasopressin-like antidiuretic effect,
but at physiologic concentrations, it inhibits vasopressin-
induced cAMP generation and water permeability via
Gi-coupled somatostatin receptors 1 and 2 (SSTR1 and
SSTR2), which are predominantly located in the distal
nephron and collecting tubule [83–85]. In some cells, in-
cluding cells in the distal nephron and collecting duct,
the regulation of [Ca2+]i is affected by the extracellular
Ca2+ concentration [86, 87]. This is in part due to the
Ca2+-sensing receptor (CaR), a GPCR sensing extracel-
lular Ca2+. Activation of the CaR stimulates intracellu-
lar phospholipase C, generation of IP3, and mobilization
of Ca2+ from the endoplasmic reticulum, and, in some
cells, inhibits intracellular accumulation of cAMP [88, 89].
Changes in peritubular Ca2+ affect [Ca2+]i in the cortical
thick ascending limb of Henle (CTAL), CCD, and outer
medullary collecting duct (OMCD), but not in the inner
MCD (IMCD) [86, 90]. This effect appears to be mediated
by the CaR in the CTAL, whereas there is less evidence
for this in the CCD and OMCD. Increases in luminal Ca2+
activate the CaR in IMCD and blunt the hydro-osmotic
permeability response to vasopressin [91].
Vasopressin receptor antagonists in PKD. The vaso-
pressin effect (via V2 receptors) on adenylyl cyclase
in principal cells, the collecting duct origin of cysts in
nephronophthisis, ARPKD, and ADPKD, and the cys-
togenic effect of cAMP provided a strong rationale for
treating animal models of these diseases with vasopressin
V2 receptor (VPV2R) antagonists. For this purpose we
used a non-peptide vasopressin antagonist (OPC-31260)
82 times more selective to rat V2 receptors than to rat
V1a receptors [92]. The specificity of the vasopressin V2
receptor antagonists might be important because vaso-
pressin might exert opposite effects on the collecting
ducts via V2 and V1a receptors. OPC-31260 behaves as an
inverse agonist capable of inhibiting constitutively active
V2 receptors [93].
The pcy mouse is a model of nephronophthisis caused
by a missense mutation in NPHP3, the gene mutated
in adolescent nephronophthisis. Administration of 0.1%
OPC-31260 to CD1/pcy mice between 4 and 30 weeks of
age markedly inhibited the renal accumulation of cAMP
and disease development, as reflected by lower kidney
weights, plasma blood urea nitrogen (BUN) concentra-
tions, renal cyst and fibrosis volumes, and mitotic and
apoptotic indices (Fig. 4) [9]. Administration of 0.1%
OPC-31260 to CD1/pcy mice between 15 and 30 weeks of
age markedly inhibited the renal accumulation of cAMP
levels and disease progression, as reflected by lower kid-
ney weights, plasma BUN concentrations, renal cyst and
fibrosis volumes, and mitotic and apoptotic indices. Kid-
ney weights of mice started on treatment at 15 weeks and
sacrificed at 30 weeks were significantly lower than those
of untreated mice at 15 weeks of age. This suggests that
OPC-31260 not only halted disease progression but also
induced disease regression.
The PCK rat is a model of human ARPKD caused by
a splicing mutation in Pkhd1. Administration of 0.1% or
0.05% OPC-31260 to PCK rats between 3 and 10 weeks of
age inhibited disease development, as reflected by lower
kidney weights, plasma creatinine and BUN concentra-
tions, renal cyst volumes, and mitotic and apoptotic in-
dices (Fig. 4) [9]. Fibrosis at this stage of disease is very
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mild, and a beneficial effect of borderline statistical signif-
icance was detected only in the rats receiving 0.1% OPC-
31260. By comparing the kidney weights of the treated
and untreated PCK rats to those of 10-week-old wild-
type Sprague-Dawley rats (0.80 ± 0.05% of body weight),
the estimated degree of protection by OPC-31260 is 60%
(0.05% group) to 75% (0.1% group). Administration of
0.05% OPC-31260 to PCK rats from 10 to 18 weeks of
age inhibited disease progression, as reflected by lower
kidney weights, plasma creatinine and BUN concentra-
tions, renal cyst and fibrosis volumes, mitotic and apop-
totic indices, and systolic BPs. The weights of the kidneys
at 18 weeks in the treated rats were identical to those
of the control PCK rats at 10 weeks; thus, the adminis-
tration of OPC-31260 completely halted disease progres-
sion. OPC-31260 did not have a significant effect on the
fibropolycystic liver disease, consistent with the absence
of VPV2Rs in the liver.
The Pkd−/WS25 mouse is a double heterozygote for a
Pkd2 null allele and an unstable Pkd2 WS25 mutation. It
is a model of human ADPKD (PKD2) that reliably de-
velops renal cysts within 3 months. OPC-31260 (0.05%),
administered in the diet to Pkd2−/WS25 mice between 3
and 16 weeks of age, markedly reduced the renal accu-
mulation of cAMP and inhibited disease development,
as reflected by lower kidney weights, plasma BUN con-
centrations, renal cyst and fibrosis volumes, and mitotic
and apoptotic indices (Fig. 4) [10]. The kidney weights
of treated Pkd2−/WS25 mice were similar to those of wild-
type mice (1.4 ± 0.2% of body weight), indicating that re-
nal enlargement was prevented. OPC-31260 did not have
a significant effect on polycystic liver disease.
Clinical trials
Translation of these animal studies into clinical trials
will necessitate the identification of appropriate outcome
measures. The decades-long natural history of ADPKD
makes this challenging. By the time renal function be-
gins to decline in ADPKD, the kidneys are markedly dis-
torted, and therapeutic interventions are not likely to be
effective. On the other hand, interventions at early stages
of the disease will not have an effect on renal function
within a reasonable period of study and follow-up. This
has made necessary the identification of surrogate mark-
ers of disease progression. The United States National In-
stitutes of Health initiated the Consortium for Radiologic
Imaging Studies of Polycystic Kidney Disease (CRISP)
prospective observational study to address this issue. The
CRISP cohort includes 241 patients with ADPKD who
are 15 to 45 years old and who had creatinine clearances
>70 mL/min at the beginning of the study. The primary
goals of CRISP are to determine whether renal and cyst
volumes can be accurately and reproducibly measured by
magnetic resonance imaging, whether changes in these
volumes can be detected over a short period in the early
stages of the disease, and whether these changes correlate
with decline in renal function during a follow-up period of
observation. Validation studies demonstrating the accu-
racy and reproducibility of the measurements, and cross-
sectional analysis of the baseline values demonstrating
significant correlations between structural (renal and cyst
volume) and functional parameters (BP, GFR, and al-
buminuria) have been published [94]. The third year of
follow-up has been completed and preliminary follow-up
observations reported in abstract form. The information
generated by the CRISP study will be invaluable for the
design of future clinical trials.
The effectiveness of vasopressin V2 receptor antago-
nists in animal models of PKD, their reno-selectivity (due
to the restricted expression of V2 receptors on collecting
duct principal cells and on endothelial cells), and their
apparent safety in preclinical and clinical studies makes
them attractive candidates for clinical trials in ADPKD.
Their administration to humans in phase I or phase II clin-
ical trials has not produced adverse effects except for the
expected mild to moderate thirst that was well tolerated
by all the subjects. No adverse vascular effects possibly re-
lated to vasopressin V2 receptors in endothelial cells have
been described. Several vasopressin V2 receptor antag-
onists are currently in phase III efficacy and safety trials
for hyponatremia due to the syndrome of inappropriate
antidiuretic hormone secretion (SIADH) and disorders
of water retention such as congestive heart failure and
cirrhosis [95]. Phase II studies with OPC-41061, a deriva-
tive of OPC-31260, which is a more potent antagonist for
human V2 receptors, have been initiated for ADPKD.
An increasing understanding of the PKD phenotype
at a cellular level will facilitate the identification of
other possible targets for intervention in ADPKD. A re-
cent randomized, crossover, placebo-controlled trial with
long-acting somatostatin slowed renal volume expansion
[96]. Somatostatin inhibits cAMP generation in Madin-
Darby kidney cells and in microdissected rat medullary
and cortical collecting ducts and antagonizes the effects
of vasopressin in toad urinary bladder and dog collecting
duct cells in a manner consistent with inhibition of basal
and hormone-stimulated adenylyl cyclase. Therefore, the
effectiveness of somatostatin, like the effectiveness of va-
sopressin V2 receptor antagonists in experimental ani-
mals, might be due to its effects on cAMP signaling.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chairman, Department
of Medicine, Caritas St. Elizabeth’s Medical Center,
Brighton, Massachusetts): You described the remarkable
effectiveness of vasopressin V2 receptor antagonists on
cystogenesis in animal models of PKD. Also, you pre-
sented information on the potential role of vasopressin
in hypertension in general and ADPKD-associated
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hypertension in particular. Activation of the V1a receptor
constricts vascular smooth muscle and promotes cardiac
hypertrophy and remodeling. Experience with combined
V1a and V2 receptor antagonists has demonstrated ef-
fectiveness in promoting aquaresis in animal and human
studies. Might one consider using such dual antagonists
in PKD in the hope of benefiting the vasculature and the
heart in addition to ameliorating cystogenesis?
DR. TORRES: Combined V1a and V2 receptor an-
tagonists might provide additional benefits. However,
V1a antagonism could also be detrimental. Activation
of the Gq-coupled V1a receptor stimulates phospholi-
pase C and PI3-induced Ca2+ release from the endo-
plasmic reticulum and can lower cAMP by inhibiting
its synthesis or promoting its degradation. Observations
in 5/6 nephrectomized Brattleboro rats with central di-
abetes insipidus also suggest that V1a activation has a
renoprotective effect. Bouby, Hassler, and Bankir [27]
treated 5/6 nephrectomized Brattleboro rats by continu-
ous infusion of equivalent doses of vasopressin (V1 and
V2 effect) or dDAVP (V2 effect only) for 13 weeks.
The rats treated with DDAVP, but not those treated
with arginine vasopressin (AVP), developed more se-
vere renal insufficiency and proteinuria than did control
nephrectomized animals. The authors suggested that the
V1a effects of vasopressin afford a relative protection
against the deleterious effects of V2 stimulation. There-
fore, studies will be necessary to determine whether V1a
receptor inhibition is neutral, favorable, or detrimental
in ADPKD.
DR. MADIAS: The phenomenon of vasopressin escape
has been described in experimental SIADH in the rat
consisting of a decrease in urine osmolality despite con-
tinued dDAVP infusion. Several mechanisms mediate
this phenomenon, including adjustments in PGE2 and
AQP2 as well as hemodynamic changes. Given that va-
sopressin represents the main regulator of cAMP levels
in the collecting tubule, have any observations suggested
the emergence of an analogous vasopressin escape in ex-
perimental models of PKD?
DR. TORRES: The model of experimental SIADH in
the rat is induced by a combination of sustained dDAVP
administration and a liquid diet that results in water
loading and hyponatremic volume expansion. Since hy-
ponatremic hypervolemia does not occur in ADPKD, the
mechanisms responsible for the vasopressin escape might
not be relevant to this disease. The vasopressin escape is
accompanied by an attenuation of the AQP2 increase
induced by the administration of dDAVP, and its initia-
tion coincides with a down-regulation of AQP2 mRNA
and protein [97, 98]. Vasopressin V2 receptor expres-
sion is often reduced in high vasopressin states, including
not only the vasopressin escape, but also conditions in
which the renal concentrating capacity is intact, such as
dehydration [99, 100]. Therefore, its contribution to the
down-regulation of AQP2 and impairment of concentrat-
ing capacity is uncertain. The levels of renal medullary
cAMP during vasopressin escape are either normal or
reduced [97, 98]. Contrary to the phenomenon of vaso-
pressin escape, the expression of vasopressin V2 receptor
and AQP2 and the levels of renal cAMP are consistently
elevated in animal models of PKD.
DR. MADIAS: Somatostatin inhibits growth hormone,
insulin, glucagon, and a number of other hormones of the
central nervous and gastrointestinal systems. Could you
please comment on the potential adverse effects of utiliz-
ing long-term somatostatin administration as treatment
of PKD?
DR. TORRES: Somatostatin has a number of potential
side effects, the most common being diarrhea and nausea,
hyperglycemia, and development of gallstones. Rugge-
nenti et al [96] administered long-acting octreotide for
6 months to 14 patients with ADPKD. Overall, the drug
was well tolerated. Two patients withdrew from the study,
one because of development of asymptomatic gallstones
and another because of fatigue. Of the remaining 12 pa-
tients, 3 had transient watery diarrhea.
DR. ANDREW S. LEVEY (Division of Nephrology,
Tufts-New England Medical Center, Boston, Massa-
chusetts): In principle, one should be able to lower plasma
vasopressin levels by water ingestion. Have you tried this
in experimental animals to see whether administration
of water can lower the vasopressin levels and achieve the
same results?
DR. TORRES: We tried years ago in a different animal
model of PKD, the Han:SPRD rat. In this model, water
loading did not have a significant beneficial effect [ab-
stract; Torres VE, et al: XIII Int Cong Nephrol p 557,
1995]. However, the cysts in the Han:SPRD rat derive
from proximal tubules. It would be worthwhile repeating
these studies in animal models with cysts from the distal
nephron and collecting duct that more closely resemble
human PKD (PCK rat, Pkd2WS25/− and pcy mice). If wa-
ter loading is found to have a beneficial effect, it might
not be to the degree observed with the vasopressin V2 re-
ceptor antagonist. The overexpression of vasopressin V2
receptors might make the polycystic kidneys very sensi-
tive to even small amounts of vasopressin that might be
difficult to turn off completely by having the patient drink
water. A limitation in trying to take this approach to pa-
tients is the issue of compliance. Inducing an aquaretic re-
sponse with a vasopressin V2 receptor antagonist would
likely increase compliance with fluid intake.
DR. LEVEY: Does the vasopressin antagonist induce
polyuria?
DR. TORRES: Yes. Interestingly, many patients with
ADPKD already have mild to moderate polyuria because
of a renal concentrating defect. The goal of treatment
with a vasopressin V2 receptor antagonist would be to in-
crease moderately the urine output to ensure inhibition of
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cAMP production and sustained hyposthenuria. A com-
promise between tolerability and desired pharmacologic
effect will be essential.
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine, and Division of Nephrol-
ogy, Tufts-New England Medical Center, Boston,
Massachusetts): You mentioned the possibility that
vasopressin is directly linked to hypertension and hy-
pertensive nephrosclerosis. Have any studies in the
experimental models of PKD examined the levels of va-
sopressin versus the levels of BP?
DR. TORRES: Plasma vasopressin levels are increased
in the pcy mouse (Vincent Gattone, personal communi-
cation). This is the only information available in animal
models. No studies have examined vasopressin levels in
relation to BP.
DR. HARRINGTON: Dr. Vito Campese recently spoke
here about the impact of the sympathetic nervous system
in a number of human and experimental renal diseases.
He mentioned that sympathetic nervous system activity
was stimulated early in PKD. Have either you or others
examined what effect the receptor antagonist has on the
sympathetic nervous system?
DR. TORRES: No, we have not studied the effect of the
vasopressin V2 receptor antagonist on the sympathetic
nervous system. We have studied the effect of renal den-
ervation on PKD in the Han:SPRD rat and found that
it had a protective effect [abstract, Khraibi AA, et al,
FASEB J 11:A82, 1997].
DR. RONALD PERRONE (Division of Nephrology,
Tufts-New England Medical Center): You indicated that
vasopressin levels are elevated in PKD. Is this a primary
defect or the result of the concentrating defect? That is, is
there a pituitary problem that results in increased vaso-
pressin release, or do these patients have a concentrating
defect and the vasopressin release is secondary to that?
DR. TORRES: Two studies, to my knowledge, have
shown that plasma vasopressin levels are increased in
ADPKD. Michalski and Grzeszczak [11] found that
ADPKD patients with normal renal function had higher
plasma vasopressin levels than did controls. An earlier
study by Danielsen et al [7] found increased vasopressin
levels in ADPKD patients with normal renal function, but
only in those with hypertension. Seeman et al [6] found an
inverse correlation between the concentration defect and
hypertension; the children who were less able to concen-
trate the urine had higher BPs. Possibly the children with
the more severe concentration defect had higher circu-
lating vasopressin that contributed to the hypertension,
but vasopressin levels were not measured in this study.
Similarly, the MDRD study noted an inverse correlation
between urine output and BP [12]. The patients with the
highest urine outputs had the highest BPs.
DR. PERRONE: I’m interested in your comment that
most of the cysts in ADPKD derive from the distal
nephron or the collecting duct. In a prior study, we eval-
uated human polycystic kidneys for expression of AQP1
and 2. These studies demonstrated proximal nephron or
descending thin limb origin for 71% of cysts. Aquaporin
2 was expressed in only 8% of cysts [101].
DR. TORRES: The cysts in ADPKD have been con-
sidered to originate from all segments of the nephron
and collecting duct. I reviewed in my presentation the
evidence that led me to suggest that the cysts at early
stages of the disease derive predominantly from the distal
nephron and collecting ducts. A problem with immuno-
histochemical studies of polycystic kidneys is that they
have mainly utilized end-stage kidneys removed prior to
renal transplantation. Tubular dilation is common in end-
stage kidneys because of causes other than PKD. The
cysts in acquired renal cystic disease are mostly of prox-
imal tubular origin. In the studies of polycystic kidneys,
it can be difficult to separate dilated tubules of end-stage
renal failure and cysts of ADPKD. The diameter of the lu-
men can help distinguish between them. Verani and Silva
[66] and Devuyst et al [68] studied cysts measuring at least
1 mm in diameter. None of these cysts in one study and
only 11% in the other study stained with proximal tubule
markers. I believe that your immunohistochemical anal-
ysis did not take into consideration the luminal sizes of
the cysts [101].
DR. BERTRAND L. JABER (Vice Chairman for Clin-
ical Affairs, Department of Medicine, Caritas St. Eliza-
beth’s Medical Center, Brighton, Massachusetts): I have a
follow-up question to Dr. Harrington’s pertaining to the
sympathetic nervous system activity. If a bulky polycys-
tic kidney is indeed the source of increased sympathetic
nervous system activity through stretch receptors and in-
creased afferent stimuli to the central nervous system,
this mechanism could be a major source of vasopressin
release. If so, why not block vasopressin release either by
physical or chemical denervation of the sympathetic ner-
vous system? This could be achieved surgically or medi-
cally using alpha-2-adrenoceptor agonist agents exerting
central sympatholytic effects, or alpha- and beta-blockers
exerting peripheral sympatholytic effects.
DR. TORRES: It would be interesting to test this hy-
pothesis in an animal model.
Dr. Jaber: If this hypothesis were to be proven in clin-
ical trials, would you foresee the use of central or pe-
ripheral sympatholytic agents as preferred agents for the
treatment of hypertension in patients with polycystic kid-
ney disease? It would seem to me that this approach
would have stronger scientific merit than the use of block-
ers of the renin-angiotensin system.
DR. TORRES: These are different avenues for explor-
ing potential therapeutic interventions targeting distinct
underlying pathogenic mechanisms.
DR. MADIAS: Are other strategies being pursued to
influence favorably cystogenesis, for example, strategies
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focusing on [Ca2+]i or the Ras/Raf/mitogen-activated
protein kinase (MAPK)/ERK signaling system?
DR. TORRES: Yes. An interesting experiment would
be to use a calcimimetic agent. Avner et al have pub-
lished extensively on the use of epidermal growth fac-
tor (EGF) tyrosine kinase inhibitors and more recently
Src inhibitors [abstract, vonVigier RO, et al, J Am Soc
Nephrol 14:110A, 2003]. Statins have been beneficial
in one animal model, because they interfere with Ras
signaling [102]. Raf kinase inhibitors should be consid-
ered in view of the likely role of B-Raf in cystogenesis.
Rapamycin has been used successfully in the Han:SPRD
rat by the Colorado group [103]. Confirmation in other
animal models is needed. Rho A inhibitors, which reduce
renal fibrosis in the 5/6 nephrectomy model, might be
worth considering. So many possibilities will need further
testing in animal models before they can be considered
for clinical trial. Maybe, at the end of the day, a combina-
tion of various medications will be necessary to optimize
efficacy and minimize toxicity.
DR. HARRINGTON: You mentioned that trials have
started using the V2 receptor antagonists in water reten-
tion states. Could you tell us what’s known either about
results or, more importantly, about the toxicity that has
been seen to date?
DR. TORRES: Vasopressin V2 receptor antagonists
have been used in clinical trials for congestive heart fail-
ure or cirrhosis with hyponatremia. Although these trials
have all been of short duration, the medications have
been well tolerated. The only side effects have been in-
creased urine output, thirst, and dry mouth.
Reprint requests to Dr. Vicente Torres, Division of Nephrology and
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